Provide feedbackProvide feedback

« Back

Lilly licenses NK-1R antagonist to Vanda Pharmaceuticals

Monday, April 16 2012 | Comments
Evidence Grade 0 What's This?
Eli Lilly and Co. licensed the worldwide rights to LY686017, an investigational small molecule neurokinin 1 receptor (NK-1R) antagonist, to Vanda Pharmaceuticals Inc.

The agreement grants Vanda exclusive rights to the drug, which will now be known as VLY-686, in all human indications.

The terms of the agreement state that Vanda will pay an initial license fee of $1 million and will be responsible for all development costs. Lilly is eligible to receive development and commercialization milestone payments, as well as tiered royalties on net sales. The potential milestone payments include $4 million for milestones achieved prior to approval of a New Drug Application by the Food and Drug Administration and as much as $95 million in future regulatory and sales milestone payments.

Vanda noted that NK-1R antagonists have been evaluated in several indications, including chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), alcohol dependence, anxiety, depression and pruritus.

The firm added that VLY-686 has demonstrated proof of concept in alcohol dependence. In a study published by the National Institutes of Health, the drug reduced alcohol cravings and voluntary alcohol consumption among patients with alcohol dependence.

According to Vanda, the only NK-1R antagonist that is currently marketed in the United States is Merck & Co. Inc.'s Emend (aprepitant), which is approved for the treatment of CINV and the prevention of PONV.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.